GT103_HCRN_NSCLC (Non-Small Cell Lung Cancer)

What is the Purpose of this Study?

This study has 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you are eligible for the dosing period

If you are eligible for the dosing period, you will:
- Have blood draws
- Have imaging scans (CT and MRI)
- Receive the study drug in combination with another drug called pembrolizumab

Both drugs are given by injection into a vein (IV) every 3 weeks. The study regimen will continue for as long as you and your doctor believe that you are benefitting from it.
What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with advanced non-small cell lung cancer

- Have received prior therapy for their cancer

For more information about who can be in this study, please contact the study team at

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if an investigational drug called GT-103 (the study drug) is a safe and effective treatment for NSCLC.

Study Details

Full Title
A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Principal Investigator

Protocol Number

View on